COVID-19特异性和非COVID-19特异性死亡的预测因素：台湾队列研究。

IF 1.4 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Asia-Pacific Journal of Public Health Pub Date : 2024-11-01 Epub Date: 2024-09-23 DOI:10.1177/10105395241282634

Shang-Yih Chan, Hsin-Hao Lai, Yun-Ju Lai, Chao-Ming Huang, Chu-Chieh Chen, Shen-Shong Chang, Yung-Feng Yen, Yi-Chun Chiu

{"title":"COVID-19特异性和非COVID-19特异性死亡的预测因素：台湾队列研究。","authors":"Shang-Yih Chan, Hsin-Hao Lai, Yun-Ju Lai, Chao-Ming Huang, Chu-Chieh Chen, Shen-Shong Chang, Yung-Feng Yen, Yi-Chun Chiu","doi":"10.1177/10105395241282634","DOIUrl":null,"url":null,"abstract":"Predictors for coronavirus disease 2019 (COVID-19)-specific and non-COVID-19-specific deaths have not been extensively studied. This cohort study in Taiwan investigated predictors for COVID-19-specific and non-COVID-19-specific deaths among hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. From January to July 2022, 2196 COVID-19 patients at Taipei City Hospital were consecutively recruited in this cohort study. Among the 175 deceased COVID-19 patients, 147 (84.0%) and 28 (16.0%) had COVID-19-specific and non-COVID-19-specific deaths, respectively. After controlling for other covariates, multinomial logistic regressions showed that age ≥ 65 was significantly associated with higher risks for both COVID-19-specific, adjusted odds ratio (AOR) = 6.21; and non-COVID-19-specific deaths (AOR = 6.06). Fully vaccinated individuals (AOR = 0.50) and Paxlovid recipients (AOR = 0.45) had lower COVID-19-specific death risks, while comorbid cancer or end-stage renal disease patients faced higher risks of non-COVID-19-specific deaths. Our study findings suggest that vaccination and Paxlovid treatment are crucial for reducing SARS-CoV-2-specific mortalities, while comorbid patients need careful monitoring to reduce non-COVID-19-specific deaths.","PeriodicalId":55570,"journal":{"name":"Asia-Pacific Journal of Public Health","volume":" ","pages":"730-737"},"PeriodicalIF":1.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictors for COVID-19-Specific and Non-COVID-19-Specific Deaths: A Cohort Study in Taiwan.\",\"authors\":\"Shang-Yih Chan, Hsin-Hao Lai, Yun-Ju Lai, Chao-Ming Huang, Chu-Chieh Chen, Shen-Shong Chang, Yung-Feng Yen, Yi-Chun Chiu\",\"doi\":\"10.1177/10105395241282634\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Predictors for coronavirus disease 2019 (COVID-19)-specific and non-COVID-19-specific deaths have not been extensively studied. This cohort study in Taiwan investigated predictors for COVID-19-specific and non-COVID-19-specific deaths among hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. From January to July 2022, 2196 COVID-19 patients at Taipei City Hospital were consecutively recruited in this cohort study. Among the 175 deceased COVID-19 patients, 147 (84.0%) and 28 (16.0%) had COVID-19-specific and non-COVID-19-specific deaths, respectively. After controlling for other covariates, multinomial logistic regressions showed that age ≥ 65 was significantly associated with higher risks for both COVID-19-specific, adjusted odds ratio (AOR) = 6.21; and non-COVID-19-specific deaths (AOR = 6.06). Fully vaccinated individuals (AOR = 0.50) and Paxlovid recipients (AOR = 0.45) had lower COVID-19-specific death risks, while comorbid cancer or end-stage renal disease patients faced higher risks of non-COVID-19-specific deaths. Our study findings suggest that vaccination and Paxlovid treatment are crucial for reducing SARS-CoV-2-specific mortalities, while comorbid patients need careful monitoring to reduce non-COVID-19-specific deaths.\",\"PeriodicalId\":55570,\"journal\":{\"name\":\"Asia-Pacific Journal of Public Health\",\"volume\":\" \",\"pages\":\"730-737\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia-Pacific Journal of Public Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10105395241282634\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific Journal of Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10105395241282634","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

摘要

有关冠状病毒病2019（COVID-19）特异性死亡和非COVID-19特异性死亡的预测因素尚未得到广泛研究。这项在台湾开展的队列研究调查了严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）感染住院患者中COVID-19特异性和非COVID-19特异性死亡的预测因素。这项队列研究连续招募了2022年1月至7月期间台北市立医院的2196名COVID-19患者。在175名COVID-19死亡患者中，分别有147人（84.0%）和28人（16.0%）死于COVID-19特异性感染和非COVID-19特异性感染。在控制了其他协变量后，多项式逻辑回归结果显示，年龄≥65与COVID-19特异性死亡和非COVID-19特异性死亡的较高风险显著相关，调整后的几率比（AOR）=6.21；95%置信区间（CI）[3.12, 12.35]；AOR=6.06；95%置信区间（CI）[1.34, 27.34]）。完全接种疫苗者（AOR = 0.50；95% CI [0.33，0.74]）和Paxlovid受试者（AOR = 0.45；95% CI [0.20，0.98]）的COVID-19特异性死亡风险较低，而合并癌症或终末期肾病患者的非COVID-19特异性死亡风险较高。我们的研究结果表明，疫苗接种和百服宁治疗对降低 SARS-CoV-2 特异性死亡至关重要，而合并症患者则需要仔细监测，以降低非 COVID-19 特异性死亡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Predictors for COVID-19-Specific and Non-COVID-19-Specific Deaths: A Cohort Study in Taiwan.

Predictors for coronavirus disease 2019 (COVID-19)-specific and non-COVID-19-specific deaths have not been extensively studied. This cohort study in Taiwan investigated predictors for COVID-19-specific and non-COVID-19-specific deaths among hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. From January to July 2022, 2196 COVID-19 patients at Taipei City Hospital were consecutively recruited in this cohort study. Among the 175 deceased COVID-19 patients, 147 (84.0%) and 28 (16.0%) had COVID-19-specific and non-COVID-19-specific deaths, respectively. After controlling for other covariates, multinomial logistic regressions showed that age ≥ 65 was significantly associated with higher risks for both COVID-19-specific, adjusted odds ratio (AOR) = 6.21; and non-COVID-19-specific deaths (AOR = 6.06). Fully vaccinated individuals (AOR = 0.50) and Paxlovid recipients (AOR = 0.45) had lower COVID-19-specific death risks, while comorbid cancer or end-stage renal disease patients faced higher risks of non-COVID-19-specific deaths. Our study findings suggest that vaccination and Paxlovid treatment are crucial for reducing SARS-CoV-2-specific mortalities, while comorbid patients need careful monitoring to reduce non-COVID-19-specific deaths.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Asia-Pacific Journal of Public Health 医学-公共卫生、环境卫生与职业卫生

CiteScore

3.30

自引率

4.00%

发文量

147

审稿时长

6 months

期刊介绍： Asia-Pacific Journal of Public Health (APJPH) is a peer-reviewed, bimonthly journal that focuses on health issues in the Asia-Pacific Region. APJPH publishes original articles on public health related issues, including implications for practical applications to professional education and services for public health and primary health care that are of concern and relevance to the Asia-Pacific region.